Malaysian manufacturing unlocks global potential for high growth MedTechs

ITL Health Group (ASX:ITD) is continuing to build its portfolio of products within the lucrative $3.3b (and growing) global blood culture testing market. Its subsidiary ITL BioMedical launched its latest blood culture testing product earlier this year (March 2018) and there are plans to bring a further pipeline of new products to market in the current financial year.

ITL Health Group serving manufacturing needs of high growth MedTechs from Malaysia

Read More “Malaysian manufacturing unlocks global potential for high growth MedTechs” »